OS Therapies Incorporated (OSTX)

NYSEAMERICAN: OSTX · Real-Time Price · USD
2.055
+0.015 (0.74%)
Oct 10, 2025, 10:53 AM EDT - Market open
0.74%
Market Cap65.03M
Revenue (ttm)n/a
Net Income (ttm)-16.25M
Shares Out 31.65M
EPS (ttm)-0.74
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume934,197
Open2.100
Previous Close2.040
Day's Range2.000 - 2.100
52-Week Range1.120 - 7.000
Betan/a
AnalystsStrong Buy
Price Target18.00 (+775.91%)
Earnings DateNov 14, 2025

About OSTX

OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. Its pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate (ADC) silicone dioxide linker technology, with a plug-and-play platform that features tunable pH sensitive silicone linkers. OS Therapies Incorporated was incorporated in 2018 a... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Aug 1, 2024
Employees 5
Stock Exchange NYSEAMERICAN
Ticker Symbol OSTX
Full Company Profile

Financial Performance

Financial Statements

Analyst Summary

According to 3 analysts, the average rating for OSTX stock is "Strong Buy." The 12-month stock price target is $18.0, which is an increase of 775.91% from the latest price.

Price Target
$18.0
(775.91% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

OS Therapies Announces Statistically Significant Positive Final 2-Year Overall Survival Data from Phase 2b Trial of OST-HER2 in the Prevention or Delay of Recurrent, Fully-Resected, Pulmonary Metastatic Osteosarcoma

75% of OST-HER2 treated patients achieved 2-year overall survival compared with 40% in the historical control group (p < 0.0001) 100% of patients who achieved 12 month event free survival achieved 2 y...

4 hours ago - Newsfile Corp

OS Therapies Provides Positive EMA Regulatory Update Following Positive Rapporteur Meeting

Overall survival recognized as key efficacy endpoint in osteosarcoma, where no standard of care exists Rapporteur highlights potential broader benefits of OST-HER2 in pulmonary and primary osteosarcom...

1 day ago - Newsfile Corp

OS Therapies to Participate in Fall 2025 Conferences and Events

Daytime Emmy Awards participation - 2 nomination for 'Shelter Me: Cancer Pioneers' Comparative Oncology documentary that features clinicians, veterinarians and human & canine patients who participated...

2 days ago - Newsfile Corp

OS Therapies Provides OST-HER2 UK MHRA and US FDA Osteosarcoma Regulatory Update

Company updates sequence of OST-HER2 regulatory submissions, prioritizing UK MHRA conditional Marketing Authorisation Application (MAA) submission following positive August 2025 Scientific Advice Meet...

10 days ago - Newsfile Corp

OS Therapies to Participate in Spotlight Panel at BioFuture 2025 October 13 11:00am EDT

New York, New York--(Newsfile Corp. - September 19, 2025) - OS Therapies Inc. (NYSE American: OSTX) ("OS Therapies" or "the Company"), a clinical-stage cancer immunotherapy and antibody drug conjugate...

21 days ago - Newsfile Corp

OS Therapies Announces Last Patient Enrolled in OST-504 (previously ADXS-504) Phase 1b Prostate Cancer Clinical Trial Completes Last Visit

Clinical data from Phase 1b prostate cancer trial to be released in Q4/25 Additionally, updated 2-year overall survival data from all 40 patients in the Phase 2b clinical trial of OST-HER2 in the prev...

4 weeks ago - Newsfile Corp

Stonegate Capital Partners Initiates Coverage on OS Therapies Inc. (OSTX)

Dallas, Texas--(Newsfile Corp. - September 8, 2025) - OS Therapies Inc. (NYSE American: OSTX): Stonegate Capital Partners initiates their coverage on OS Therapies Inc. (NYSE American: OSTX). OS Therap...

4 weeks ago - Newsfile Corp

OS Therapies to Participate in Upcoming Investor Conferences in September 2025

New York, New York--(Newsfile Corp. - September 3, 2025) - OS Therapies Inc. (NYSE American: OSTX) ("OS Therapies" or "the Company"), a clinical-stage cancer immunotherapy and antibody drug conjugate ...

5 weeks ago - Newsfile Corp

OS Therapies Provides OST-HER2 Recurrent, Fully Resected, Pulmonary Metastatic Osteosarcoma Program Update Following FDA End of Phase 2 Meeting

Company on track to begin submission of a rolling Biologics Licensing Application (BLA) request for OST-HER2 to U.S. Food & Drug Administration in September 2025 New York, New York--(Newsfile Corp. - ...

5 weeks ago - Newsfile Corp

OS Therapies Completes Exercise Inducement and Exchange Offer for All Remaining Outstanding Warrants Issued in Connection with December 2024 Financing

All remaining holders of outstanding warrants with $1.12 per share exercise price have participated, raising $3.7 million in gross proceeds to be used to accelerate OST-HER2 commercial launch preparat...

5 weeks ago - Newsfile Corp

OS Therapies to Provide OST-HER2 Recurrent, Fully Resected, Pulmonary Metastatic Osteosarcoma FDA End of Phase 2 Meeting Update on Tuesday, September 2, 2025

New York, New York--(Newsfile Corp. - August 27, 2025) - OS Therapies Inc. (NYSE American: OSTX) ("OS Therapies" or "the Company"), a clinical-stage cancer immunotherapy and antibody drug conjugate bi...

6 weeks ago - Newsfile Corp

OS Therapies Terminates Equity Line of Credit

New York, New York--(Newsfile Corp. - August 25, 2025) - OS Therapies Inc. (NYSE American: OSTX) ("OS Therapies" or "the Company"), a clinical-stage cancer immunotherapy and antibody drug conjugate bi...

6 weeks ago - Newsfile Corp

OS Therapies Reports Second Quarter 2025 Financial Results and Provides Business Update

U.S. FDA ("FDA") confirms OST-HER2 meets biological definition of Regenerative Medicine Advanced Therapy (RMAT) FDA issues OST-HER2 BLA number in preparation for Accelerated Approval submission follow...

7 weeks ago - Newsfile Corp

OS Therapies to Report Second Quarter 2025 Financial Results and Provide Business Update on Tuesday, August 19th, 2025

New York, New York--(Newsfile Corp. - August 14, 2025) - OS Therapies Inc. (NYSE American: OSTX) ("OS Therapies" or "the Company"), a clinical-stage cancer immunotherapy and antibody drug conjugate bi...

2 months ago - Newsfile Corp

OS Therapies Announces Statistically Significant Positive Interim 2-Year Overall Survival Data from Phase 2b Clinical Trial of OST-HER2 in the Prevention or Delay of Recurrent, Fully Resected, Pulmonary Metastatic Osteosarcoma

66.6% of OST-HER2 treated patients achieved 2-year overall survival compared with 40% in the historical control group (p = 0.0046) FDA issues Biologics Licensing Application (BLA) number for OST-HER2 ...

2 months ago - Newsfile Corp

OS Therapies Receives Positive Feedback from UK MHRA Scientific Advice Meeting and Submits Innovative Licensing and Access Pathway (ILAP) Request for OST-HER2 in the Prevention or Delay of Recurrent, Fully Resected, Pulmonary Metastatic Osteosarcoma

MHRA seeks to harmonize UK & US regulatory review via Project Orbis EMA Rapporteur Scientific Advice Meeting scheduled for October 2025 New York, New York--(Newsfile Corp. - August 7, 2025) - OS Thera...

2 months ago - Newsfile Corp

OS Therapies Closes $4.2 Million in Warrant Exercise Inducement and Exchange Offer

Cash runway extended through 2026, beyond September 30, 2026 sunset date for rare pediatric priority review voucher (PRV) program Additional funding allows Company to advance strategic alternatives fo...

3 months ago - Newsfile Corp

OS Therapies Provides Clinical & Global Regulatory Updates

End of Phase 2 Meeting with FDA scheduled for August 27, 2025 to review OST-HER2 recurrent, pulmonary metastatic osteosarcoma program Scientific Advice Meetings confirmed with global regulators in maj...

3 months ago - Newsfile Corp

OS Therapies Granted End of Phase 2 Meeting by US FDA for OST-HER2 Program in the Prevention or Delay of Recurrent, Fully Resected, Pulmonary Metastatic Osteosarcoma

NEW YORK--(BUSINESS WIRE)--OS Therapies (NYSE-A: OSTX) (“OS Therapies” or “the Company”), a clinical-stage immunotherapy and Antibody Drug Conjugate (ADC) biopharmaceutical company, today announced it...

3 months ago - Business Wire

OS Therapies Presents Statistically Significantly Positive 1-Year Event Free Survival, Overall Survival and Safety Clinical Data Updates for OST-HER2 at the MIB Agents Factor Osteosarcoma Conference

NEW YORK--(BUSINESS WIRE)--OS Therapies (NYSE-A: OSTX) (“OS Therapies” or “the Company”), a clinical-stage immunotherapy and Antibody Drug Conjugate (ADC) biopharmaceutical company, today announced po...

3 months ago - Business Wire

OS Therapies Receives Positive FDA Meeting Feedback on Regulatory Pathway for Accelerated Approval of OST-HER2 in the Prevention or Delay of Recurrent, Fully Resected, Pediatric Lung Metastatic Osteosarcoma

NEW YORK--(BUSINESS WIRE)--OS Therapies (NYSE-A: OSTX) (“OS Therapies” or “the Company”), a clinical-stage immunotherapy and Antibody Drug Conjugate (ADC) biopharmaceutical company, today announced th...

3 months ago - Business Wire

OS Therapies Announces Warrant Exercise Inducement & Exchange Offer

NEW YORK--(BUSINESS WIRE)--OS Therapies Inc. (NYSE-A: OSTX) (“OS Therapies” or “the Company”), a clinical-stage immunotherapy and Antibody Drug Conjugate (ADC) biopharmaceutical company, today announc...

3 months ago - Business Wire

OS Therapies Partners with EVERSANA for the U.S. Commercialization of OST-HER2 in Recurrent, Fully Resected, Pediatric Lung Metastatic Osteosarcoma

NEW YORK and CHICAGO , June 10, 2025 /PRNewswire/ -- OS Therapies Inc. (NYSE-A: OSTX) ("OS Therapies" or "the Company"), a clinical-stage cancer immunotherapy and antibody drug conjugate biotechnology...

4 months ago - PRNewsWire

OS Therapies Submits Request for Regenerative Medicine Advanced Therapy (RMAT) Designation to U.S. FDA for OST-HER2 in the Prevention of Metastases in Recurrent, Fully-Resected, Lung Metastatic Pediatric Osteosarcoma

NEW YORK--(BUSINESS WIRE)--OS Therapies Inc. (NYSE-A: OSTX) (“OS Therapies” or “the Company”), a clinical-stage cancer immunotherapy and antibody drug conjugate biotechnology company, today announced ...

4 months ago - Business Wire

OS Therapies Reports First Quarter 2025 Financial Results and Provides Business Update

NEW YORK--(BUSINESS WIRE)--OS Therapies Inc. (NYSE-A: OSTX) (“OS Therapies” or “the Company”), a clinical-stage cancer immunotherapy and antibody drug conjugate biotechnology company, today reported f...

5 months ago - Business Wire